{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T10:44:44Z","timestamp":1793357084759,"version":"4.5.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"NEPTUNE Consortium","award":["U54-DK-083912"],"award-info":[{"award-number":["U54-DK-083912"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["U54-DK-083912"],"award-info":[{"award-number":["U54-DK-083912"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajkd.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Kidney Diseases"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1053\/j.ajkd.2018.07.009","type":"journal-article","created":{"date-parts":[[2018,9,21]],"date-time":"2018-09-21T15:14:34Z","timestamp":1537542874000},"page":"82-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Using All Longitudinal Data to Define Time to Specified Percentages of Estimated GFR Decline: A Simulation Study"],"prefix":"10.1053","volume":"73","author":[{"given":"Jarcy","family":"Zee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H.","family":"Mariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda W.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1053\/j.ajkd.2018.07.009_bib1","doi-asserted-by":"crossref","first-page":"874","DOI":"10.2215\/CJN.00600206","article-title":"Surrogate end points for clinical trials of kidney disease progression","volume":"1","author":"Stevens","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"10.1053\/j.ajkd.2018.07.009_bib2","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","article-title":"GFR decline as an end point of clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration","volume":"64","author":"Levey","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2018.07.009_bib3","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1053\/j.ajkd.2014.09.006","article-title":"GFR decline as an end point in trials of CKD: a viewpoint from the FDA","volume":"64","author":"Thompson","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2018.07.009_bib4","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1053\/j.ajkd.2014.08.009","article-title":"Surrogate outcomes for ESRD risk: the case for a 30% reduction in estimated GFR over 2 years","volume":"64","author":"Sontrop","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"10.1053\/j.ajkd.2018.07.009_bib5","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1053\/j.ajkd.2014.08.019","article-title":"Utility and validity of estimated GFR-based surrogate time-to-event end points in CKD: a simulation study","volume":"64","author":"Greene","year":"2014","journal-title":"Am J Kidney Dis"},{"issue":"7 suppl 2","key":"10.1053\/j.ajkd.2018.07.009_bib6","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1097\/01.ASN.0000070149.78399.CE","article-title":"The Chronic Renal Insufficiency Cohort (CRIC) study: design and methods","volume":"14","author":"Feldman","year":"2003","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1053\/j.ajkd.2018.07.009_bib7","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1524-6175.2003.01924.x","article-title":"The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?","volume":"5","author":"Sica","year":"2003","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"issue":"5","key":"10.1053\/j.ajkd.2018.07.009_bib8","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.2215\/CJN.01941205","article-title":"Design and methods of the Chronic Kidney Disease in Children (CKiD) prospective cohort study","volume":"1","author":"Furth","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1053\/j.ajkd.2018.07.009_bib9","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/ki.2012.428","article-title":"Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multi-disciplinary approach","volume":"83","author":"Gadegbeku","year":"2013","journal-title":"Kidney Int"},{"key":"10.1053\/j.ajkd.2018.07.009_bib10","unstructured":"Clinical Phenotyping and Resource Biobank Core. https:\/\/kidneycenter.med.umich.edu\/clinical-phenotyping-resource-biobank-core. Accessed August 11,\u00a02018."},{"key":"10.1053\/j.ajkd.2018.07.009_bib11","series-title":"Competing Risks: A Practical Perspective","author":"Pintilie","year":"2006"}],"container-title":["American Journal of Kidney Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638618308709?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0272638618308709?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T03:04:15Z","timestamp":1759460655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0272638618308709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":11,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S0272638618308709"],"URL":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.07.009","relation":{},"ISSN":["0272-6386"],"issn-type":[{"value":"0272-6386","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Using All Longitudinal Data to Define Time to Specified Percentages of Estimated GFR Decline: A Simulation Study","name":"articletitle","label":"Article Title"},{"value":"American Journal of Kidney Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.ajkd.2018.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}]}}